{
    "data": [
        {
            "id": "3785226",
            "type": "article",
            "attributes": {
                "publishOn": "2015-12-31T11:50:30-05:00",
                "isLockedPro": false,
                "commentCount": 118,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Reviewing Gilead's Latest Pipeline News: Focus On Oncology And The Galapagos Deal",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "167762",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/3785226-reviewing-gileads-latest-pipeline-news-focus-on-oncology-and-galapagos-deal"
            }
        },
        {
            "id": "3785006",
            "type": "article",
            "attributes": {
                "publishOn": "2015-12-31T10:11:05-05:00",
                "isLockedPro": false,
                "commentCount": 67,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Premarket Biotech Digest: My Response, Gilead In 2016, Blow For Vivus",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "53222",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/3785006-premarket-biotech-digest-response-gilead-in-2016-blow-for-vivus"
            }
        },
        {
            "id": "3784146",
            "type": "article",
            "attributes": {
                "publishOn": "2015-12-30T18:24:36-05:00",
                "isLockedPro": false,
                "commentCount": 151,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead's HCV Price Disparity In Egypt Comes Under Fire",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3784146-gileads-hcv-price-disparity-in-egypt-comes-under-fire"
            }
        },
        {
            "id": "3782876",
            "type": "article",
            "attributes": {
                "publishOn": "2015-12-30T09:59:59-05:00",
                "isLockedPro": false,
                "commentCount": 35,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Cloud Of Uncertainty Has Been Covering Gilead Over The Past Year But That's Not Bad",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "44001",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3782876-cloud-of-uncertainty-covering-gilead-over-past-year-not-bad"
            }
        },
        {
            "id": "3778446",
            "type": "article",
            "attributes": {
                "publishOn": "2015-12-28T09:47:35-05:00",
                "isLockedPro": false,
                "commentCount": 146,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Will Gilead Turn The Corner In 2016?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23762",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "167561",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3778446-will-gilead-turn-corner-in-2016"
            }
        },
        {
            "id": "3775636",
            "type": "article",
            "attributes": {
                "publishOn": "2015-12-24T08:55:34-05:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Premarket Biotech Digest: Gilead's M&A Focus, MannKind Appoints CEO, Northwest Tumbles",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "53222",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/3775636-premarket-biotech-digest-gileads-m-focus-mannkind-appoints-ceo-northwest-tumbles"
            }
        },
        {
            "id": "3771186",
            "type": "article",
            "attributes": {
                "publishOn": "2015-12-22T10:14:18-05:00",
                "isLockedPro": false,
                "commentCount": 70,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences' Stake In Galapagos NV Is Not A Game Changer",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25562",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3771186-gilead-sciences-stake-in-galapagos-nv-is-not-game-changer"
            }
        },
        {
            "id": "3770546",
            "type": "article",
            "attributes": {
                "publishOn": "2015-12-22T06:34:14-05:00",
                "isLockedPro": false,
                "commentCount": 253,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: The Sign Of Things To Come?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23762",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "167371",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3770546-gilead-sign-of-things-to-come"
            }
        },
        {
            "id": "3769336",
            "type": "article",
            "attributes": {
                "publishOn": "2015-12-21T15:25:39-05:00",
                "isLockedPro": false,
                "commentCount": 95,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: A Strong Pick For Capital Preservation",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "96526",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "167344",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3769336-gilead-strong-pick-for-capital-preservation"
            }
        },
        {
            "id": "3762286",
            "type": "article",
            "attributes": {
                "publishOn": "2015-12-17T08:50:15-05:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Premarket Biotech Digest: Tracking Gilead HCV Sales, Shire-Baxalta Deal, AstraZeneca Deal",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "53222",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/3762286-premarket-biotech-digest-tracking-gilead-hcv-sales-shire-baxalta-deal-astrazeneca-deal"
            }
        },
        {
            "id": "3753156",
            "type": "article",
            "attributes": {
                "publishOn": "2015-12-14T08:30:31-05:00",
                "isLockedPro": false,
                "commentCount": 24,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Premarket Biotech Digest: Gilead's Upside, Shire-Baxalta Deal, ARIAD Lowers Guidance",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "53222",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/3753156-premarket-biotech-digest-gileads-upside-shire-baxalta-deal-ariad-lowers-guidance"
            }
        },
        {
            "id": "3750396",
            "type": "article",
            "attributes": {
                "publishOn": "2015-12-11T12:34:46-05:00",
                "isLockedPro": false,
                "commentCount": 208,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: Minimum 30% Upside In 2016",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23762",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "166951",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3750396-gilead-minimum-30-percent-upside-in-2016"
            }
        },
        {
            "id": "3748286",
            "type": "article",
            "attributes": {
                "publishOn": "2015-12-10T15:23:02-05:00",
                "isLockedPro": false,
                "commentCount": 173,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why Gilead's HCV Strategy Will Not Cause Revolts",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "87536",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "166902",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3748286-why-gileads-hcv-strategy-will-not-cause-revolts"
            }
        },
        {
            "id": "3744566",
            "type": "article",
            "attributes": {
                "publishOn": "2015-12-09T12:12:51-05:00",
                "isLockedPro": false,
                "commentCount": 157,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead's HCV Prices Are Cheaper In Europe; Will Lawmakers Revolt?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3744566-gileads-hcv-prices-are-cheaper-in-europe-will-lawmakers-revolt"
            }
        },
        {
            "id": "3743556",
            "type": "article",
            "attributes": {
                "publishOn": "2015-12-09T07:11:22-05:00",
                "isLockedPro": false,
                "commentCount": 39,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: One Of My Long-Term Favorites",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68315",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "166797",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3743556-gilead-one-of-long-term-favorites"
            }
        },
        {
            "id": "3740576",
            "type": "article",
            "attributes": {
                "publishOn": "2015-12-08T08:40:01-05:00",
                "isLockedPro": false,
                "commentCount": 75,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why I Remain Long Gilead Sciences",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25562",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "166748",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3740576-why-i-remain-long-gilead-sciences"
            }
        },
        {
            "id": "3737456",
            "type": "article",
            "attributes": {
                "publishOn": "2015-12-07T08:19:22-05:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Premarket Biotech Digest: Gilead And HCV Drug Pricing, Relypsa Rumors, Amgen-Merck Collaboration",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "53222",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/3737456-premarket-biotech-digest-gilead-and-hcv-drug-pricing-relypsa-rumors-amgen-merck-collaboration"
            }
        },
        {
            "id": "3737426",
            "type": "article",
            "attributes": {
                "publishOn": "2015-12-07T08:15:44-05:00",
                "isLockedPro": false,
                "commentCount": 97,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why Gilead Is Still A Growth Stock - Focus On HIV And China, With Projections For 2016",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "166679",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/3737426-why-gilead-is-still-growth-stock-focus-on-hiv-and-china-projections-for-2016"
            }
        },
        {
            "id": "3737096",
            "type": "article",
            "attributes": {
                "publishOn": "2015-12-07T06:37:17-05:00",
                "isLockedPro": false,
                "commentCount": 157,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: Trouble Down On The Pharm?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3737096-gilead-trouble-down-on-pharm"
            }
        },
        {
            "id": "3733486",
            "type": "article",
            "attributes": {
                "publishOn": "2015-12-04T08:44:18-05:00",
                "isLockedPro": false,
                "commentCount": 156,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: Much Ado About Nothing",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23762",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "166580",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3733486-gilead-sciences-much-ado-nothing"
            }
        },
        {
            "id": "3733476",
            "type": "article",
            "attributes": {
                "publishOn": "2015-12-04T08:41:18-05:00",
                "isLockedPro": false,
                "commentCount": 31,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: Don't Get Shocked Into Selling Or Avoiding The Stock",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25218",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "166579",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3733476-gilead-dont-get-shocked-selling-avoiding-stock"
            }
        },
        {
            "id": "3733326",
            "type": "article",
            "attributes": {
                "publishOn": "2015-12-04T07:51:54-05:00",
                "isLockedPro": false,
                "commentCount": 16,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Uncertainty In Biotech Industry Should Create Excellent Buying Opportunity For Gilead",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "44001",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "166575",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3733326-uncertainty-in-biotech-industry-should-create-excellent-buying-opportunity-for-gilead"
            }
        },
        {
            "id": "3732776",
            "type": "article",
            "attributes": {
                "publishOn": "2015-12-04T01:32:37-05:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Thanks, Gilead - Double-Digit Spending Growth Driving Tougher Payer Line",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21877",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3732776-thanks-gilead-double-digit-spending-growth-driving-tougher-payer-line"
            }
        },
        {
            "id": "3727046",
            "type": "article",
            "attributes": {
                "publishOn": "2015-12-02T08:23:29-05:00",
                "isLockedPro": false,
                "commentCount": 269,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Wyden-Grassley Findings Could Punish Gilead",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3727046-wyden-grassley-findings-punish-gilead"
            }
        },
        {
            "id": "3725296",
            "type": "article",
            "attributes": {
                "publishOn": "2015-12-01T16:34:18-05:00",
                "isLockedPro": false,
                "commentCount": 35,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead's HIV Franchise: Potential Impact Of TAF-Based Products",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "92946",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3725296-gileads-hiv-franchise-potential-impact-of-taf-based-products"
            }
        },
        {
            "id": "3725216",
            "type": "article",
            "attributes": {
                "publishOn": "2015-12-01T16:07:26-05:00",
                "isLockedPro": false,
                "commentCount": 168,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Is The Gilead Hepatitis Portfolio Set To Expand?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "93696",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "166422",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3725216-is-gilead-hepatitis-portfolio-set-to-expand"
            }
        },
        {
            "id": "3719946",
            "type": "article",
            "attributes": {
                "publishOn": "2015-11-30T08:27:55-05:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Premarket Biotech Digest: Gilead U.S. HCV Sales, Sanofi's Animal Health Unit, KaloBios Continues To Rally",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "53222",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3719946-premarket-biotech-digest-gilead-u-s-hcv-sales-sanofis-animal-health-unit-kalobios-continues"
            }
        },
        {
            "id": "3719796",
            "type": "article",
            "attributes": {
                "publishOn": "2015-11-30T07:33:19-05:00",
                "isLockedPro": false,
                "commentCount": 131,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead's HCV Sales May Have Peaked",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3719796-gileads-hcv-sales-may-peaked"
            }
        },
        {
            "id": "3714846",
            "type": "article",
            "attributes": {
                "publishOn": "2015-11-25T21:50:59-05:00",
                "isLockedPro": false,
                "commentCount": 112,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences Stock Forecast For 2016",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "50792",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "166157",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3714846-gilead-sciences-stock-forecast-for-2016"
            }
        },
        {
            "id": "3710236",
            "type": "article",
            "attributes": {
                "publishOn": "2015-11-24T11:56:54-05:00",
                "isLockedPro": false,
                "commentCount": 91,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: 92% Earnings Growth And 88% Free Cash Flow Growth",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "91305",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "166049",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3710236-gilead-sciences-92-percent-earnings-growth-and-88-percent-free-cash-flow-growth"
            }
        },
        {
            "id": "3705916",
            "type": "article",
            "attributes": {
                "publishOn": "2015-11-23T08:21:29-05:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Premarket Biotech Digest: Pfizergan, Gilead's Milestone, MannKind CEO Steps Down",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "53222",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/3705916-premarket-biotech-digest-pfizergan-gileads-milestone-mannkind-ceo-steps-down"
            }
        },
        {
            "id": "3688536",
            "type": "article",
            "attributes": {
                "publishOn": "2015-11-16T13:20:51-05:00",
                "isLockedPro": false,
                "commentCount": 153,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "The Strengthened Case For 'Risk Off': Liking Extra Cash And Some Other 'Value' Assets",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3688536-strengthened-case-for-risk-off-liking-extra-cash-and-value-assets"
            }
        },
        {
            "id": "3688136",
            "type": "article",
            "attributes": {
                "publishOn": "2015-11-16T11:55:33-05:00",
                "isLockedPro": false,
                "commentCount": 67,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Is Gilead Still An Attractive Long Term Proposition?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "96546",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "165586",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3688136-is-gilead-still-attractive-long-term-proposition"
            }
        },
        {
            "id": "3687216",
            "type": "article",
            "attributes": {
                "publishOn": "2015-11-16T08:23:31-05:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Premarket Biotech Digest: Harvoni's Label Expansion, AstraZeneca's Tagrisso Approved, KaloBios Winds Down",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "53222",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/3687216-premarket-biotech-digest-harvonis-label-expansion-astrazenecas-tagrisso-approved-kalobios"
            }
        },
        {
            "id": "3687016",
            "type": "article",
            "attributes": {
                "publishOn": "2015-11-16T07:29:35-05:00",
                "isLockedPro": false,
                "commentCount": 25,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Will The New Indications For Harvoni Increase Gilead Sciences' U.S. Sales?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22018",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "165549",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3687016-will-new-indications-for-harvoni-increase-gilead-sciences-u-s-sales"
            }
        },
        {
            "id": "3686836",
            "type": "article",
            "attributes": {
                "publishOn": "2015-11-16T06:34:46-05:00",
                "isLockedPro": false,
                "commentCount": 61,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Do You Buy Stocks Or Stock Symbols?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "94806",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "165542",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3686836-you-buy-stocks-stock-symbols"
            }
        },
        {
            "id": "3686826",
            "type": "article",
            "attributes": {
                "publishOn": "2015-11-16T06:29:28-05:00",
                "isLockedPro": false,
                "commentCount": 22,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "8 Reasons Why Gilead Is A Better Investment Than Intel And 3 Reasons Why It Is Not",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "82056",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3686826-8-reasons-why-gilead-is-better-investment-intel-and-3-reasons-why-is-not"
            }
        },
        {
            "id": "3683206",
            "type": "article",
            "attributes": {
                "publishOn": "2015-11-13T09:06:38-05:00",
                "isLockedPro": false,
                "commentCount": 264,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: Like Watching Paint Dry In 2015",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23762",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3683206-gilead-like-watching-paint-dry-in-2015"
            }
        },
        {
            "id": "3679056",
            "type": "article",
            "attributes": {
                "publishOn": "2015-11-12T08:44:25-05:00",
                "isLockedPro": false,
                "commentCount": 59,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: The Margin Of Safety Will Benefit Long-Term Investors",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "96356",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "165403",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3679056-gilead-margin-of-safety-will-benefit-long-term-investors"
            }
        },
        {
            "id": "3671726",
            "type": "article",
            "attributes": {
                "publishOn": "2015-11-10T11:53:24-05:00",
                "isLockedPro": false,
                "commentCount": 121,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: KickStart My Heart",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "89286",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "165289",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3671726-gilead-kickstart-heart"
            }
        },
        {
            "id": "3665466",
            "type": "article",
            "attributes": {
                "publishOn": "2015-11-09T08:44:29-05:00",
                "isLockedPro": false,
                "commentCount": 94,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Updating My Price Target On Gilead Sciences",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25562",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3665466-updating-price-target-on-gilead-sciences"
            }
        },
        {
            "id": "3665286",
            "type": "article",
            "attributes": {
                "publishOn": "2015-11-09T08:23:01-05:00",
                "isLockedPro": false,
                "commentCount": 44,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Premarket Biotech Digest: Anavex's Results, Gilead's HCV Sales, Sanofi's Strategic Roadmap",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "53222",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/3665286-premarket-biotech-digest-anavexs-results-gileads-hcv-sales-sanofis-strategic-roadmap"
            }
        },
        {
            "id": "3657936",
            "type": "article",
            "attributes": {
                "publishOn": "2015-11-06T14:16:47-05:00",
                "isLockedPro": false,
                "commentCount": 70,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: Years Of International Success Ahead",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68315",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3657936-gilead-years-of-international-success-ahead"
            }
        },
        {
            "id": "3657266",
            "type": "article",
            "attributes": {
                "publishOn": "2015-11-06T12:11:34-05:00",
                "isLockedPro": false,
                "commentCount": 213,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead - Good Newsflow Accelerates; All-Time Highs Now Achievable",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "165083",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3657266-gilead-good-newsflow-accelerates-all-time-highs-now-achievable"
            }
        },
        {
            "id": "3656836",
            "type": "article",
            "attributes": {
                "publishOn": "2015-11-06T10:32:20-05:00",
                "isLockedPro": false,
                "commentCount": 16,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Premarket Biotech Digest: Gene Editing, Gilead's Genvoya Approved, Celgene Misses",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "53222",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/3656836-premarket-biotech-digest-gene-editing-gileads-genvoya-approved-celgene-misses"
            }
        },
        {
            "id": "3637066",
            "type": "article",
            "attributes": {
                "publishOn": "2015-11-03T09:10:47-05:00",
                "isLockedPro": false,
                "commentCount": 141,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Biotechs Blast Off: Could The 1999 Scenario Be In Play?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "164838",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/3637066-biotechs-blast-off-1999-scenario-be-in-play"
            }
        },
        {
            "id": "3635576",
            "type": "article",
            "attributes": {
                "publishOn": "2015-11-03T00:41:13-05:00",
                "isLockedPro": false,
                "commentCount": 84,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: Potential Acquisition Candidates",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25218",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3635576-gilead-sciences-potential-acquisition-candidates"
            }
        },
        {
            "id": "3632256",
            "type": "article",
            "attributes": {
                "publishOn": "2015-11-02T08:25:05-05:00",
                "isLockedPro": false,
                "commentCount": 19,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Premarket Biotech Digest: Tax Inversion Deals, Gilead's HIV Franchise, AbbVie's Outlook",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "53222",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/3632256-premarket-biotech-digest-tax-inversion-deals-gileads-hiv-franchise-abbvies-outlook"
            }
        },
        {
            "id": "3625186",
            "type": "article",
            "attributes": {
                "publishOn": "2015-10-30T07:43:34-04:00",
                "isLockedPro": false,
                "commentCount": 129,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences Stock Isn't Sexy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "74295",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "164666",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3625186-gilead-sciences-stock-isnt-sexy"
            }
        },
        {
            "id": "3625166",
            "type": "article",
            "attributes": {
                "publishOn": "2015-10-30T07:40:38-04:00",
                "isLockedPro": false,
                "commentCount": 79,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: 25 Billion Reasons For Investors To Stay The Course - A Major Acquisition Is Coming",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "65263",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "164664",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3625166-gilead-25-billion-reasons-for-investors-to-stay-course-major-acquisition-is-coming"
            }
        },
        {
            "id": "3621446",
            "type": "article",
            "attributes": {
                "publishOn": "2015-10-29T15:34:40-04:00",
                "isLockedPro": false,
                "commentCount": 17,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences May Be In A Lull, But Its Potential And Its History Make It Attractive",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21305",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3621446-gilead-sciences-may-be-in-lull-potential-and-history-make-attractive"
            }
        },
        {
            "id": "3618496",
            "type": "article",
            "attributes": {
                "publishOn": "2015-10-29T08:10:13-04:00",
                "isLockedPro": false,
                "commentCount": 111,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "The Market Is Wrong About Gilead Sciences' Growth Prospects",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22018",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "164595",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3618496-market-is-wrong-gilead-sciences-growth-prospects"
            }
        },
        {
            "id": "3614086",
            "type": "article",
            "attributes": {
                "publishOn": "2015-10-28T12:25:00-04:00",
                "isLockedPro": false,
                "commentCount": 44,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences Beats Expectations Again",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "92946",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3614086-gilead-sciences-beats-expectations-again"
            }
        },
        {
            "id": "3613746",
            "type": "article",
            "attributes": {
                "publishOn": "2015-10-28T11:25:25-04:00",
                "isLockedPro": false,
                "commentCount": 224,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead's Q3 Beats, The Street Shrugs: Why I'm Happy To Stay The Course",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "164548",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/3613746-gileads-q3-beats-street-shrugs-why-happy-to-stay-course"
            }
        },
        {
            "id": "3612906",
            "type": "article",
            "attributes": {
                "publishOn": "2015-10-28T08:52:56-04:00",
                "isLockedPro": false,
                "commentCount": 178,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "My Take On Gilead Post-Earnings",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23762",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "164530",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3612906-take-on-gilead-post-earnings"
            }
        },
        {
            "id": "3612526",
            "type": "article",
            "attributes": {
                "publishOn": "2015-10-28T07:44:39-04:00",
                "isLockedPro": false,
                "commentCount": 41,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Next Quarter, Next Earnings Beat For Gilead",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68315",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3612526-next-quarter-next-earnings-beat-for-gilead"
            }
        },
        {
            "id": "3606806",
            "type": "article",
            "attributes": {
                "publishOn": "2015-10-27T08:44:55-04:00",
                "isLockedPro": false,
                "commentCount": 23,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Premarket Biotech Digest: Gilead's Earnings, Pfizer Beats, Anavex Achieves Milestone",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "53222",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3606806-premarket-biotech-digest-gileads-earnings-pfizer-beats-anavex-achieves-milestone"
            }
        },
        {
            "id": "3606736",
            "type": "article",
            "attributes": {
                "publishOn": "2015-10-27T08:34:15-04:00",
                "isLockedPro": false,
                "commentCount": 45,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: The Pharm Will Deliver On Tuesday",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3606736-gilead-pharm-will-deliver-on-tuesday"
            }
        },
        {
            "id": "3603796",
            "type": "article",
            "attributes": {
                "publishOn": "2015-10-26T13:06:18-04:00",
                "isLockedPro": false,
                "commentCount": 141,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "If It Happened To AbbVie, Could It Also Happen To Gilead?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24491",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3603796-happened-to-abbvie-also-happen-to-gilead"
            }
        },
        {
            "id": "3602376",
            "type": "article",
            "attributes": {
                "publishOn": "2015-10-26T07:32:06-04:00",
                "isLockedPro": false,
                "commentCount": 39,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "4 Key Points To Watch From Gilead Sciences' Upcoming Earnings Release",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25562",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3602376-4-key-points-to-watch-from-gilead-sciences-upcoming-earnings-release"
            }
        },
        {
            "id": "3602166",
            "type": "article",
            "attributes": {
                "publishOn": "2015-10-26T06:37:03-04:00",
                "isLockedPro": false,
                "commentCount": 16,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "What To Expect From Gilead Sciences' Earnings Report",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22018",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3602166-what-to-expect-from-gilead-sciences-earnings-report"
            }
        },
        {
            "id": "3600456",
            "type": "article",
            "attributes": {
                "publishOn": "2015-10-25T13:23:40-04:00",
                "isLockedPro": false,
                "commentCount": 87,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: A Winner On 3 Fronts",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23762",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "164297",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3600456-gilead-winner-on-3-fronts"
            }
        },
        {
            "id": "3597836",
            "type": "article",
            "attributes": {
                "publishOn": "2015-10-23T09:02:51-04:00",
                "isLockedPro": false,
                "commentCount": 17,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Premarket Biotech Digest: Gilead Gets A Boost, Zafgen's Beloranib Program, Relypsa Gets FDA Nod",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "53222",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/3597836-premarket-biotech-digest-gilead-gets-boost-zafgens-beloranib-program-relypsa-gets-fda-nod"
            }
        },
        {
            "id": "3597616",
            "type": "article",
            "attributes": {
                "publishOn": "2015-10-23T07:24:21-04:00",
                "isLockedPro": false,
                "commentCount": 80,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Gains From AbbVie's Pain",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "164240",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3597616-gilead-gains-from-abbvies-pain"
            }
        },
        {
            "id": "3595426",
            "type": "article",
            "attributes": {
                "publishOn": "2015-10-22T17:10:51-04:00",
                "isLockedPro": false,
                "commentCount": 56,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Pops Today- Still A Buy Pre Earnings?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68315",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "164211",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3595426-gilead-pops-today-still-buy-pre-earnings"
            }
        },
        {
            "id": "3595396",
            "type": "article",
            "attributes": {
                "publishOn": "2015-10-22T17:07:07-04:00",
                "isLockedPro": false,
                "commentCount": 415,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Implications For Gilead Of The Problems With AbbVie's Competitive Hepatitis C Product",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "164210",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/3595396-implications-for-gilead-of-problems-abbvies-competitive-hepatitis-c-product"
            }
        },
        {
            "id": "3583246",
            "type": "article",
            "attributes": {
                "publishOn": "2015-10-20T16:35:40-04:00",
                "isLockedPro": false,
                "commentCount": 77,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why I Have Increased My Long Position In Gilead",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "32141",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3583246-why-i-increased-long-position-in-gilead"
            }
        },
        {
            "id": "3582506",
            "type": "article",
            "attributes": {
                "publishOn": "2015-10-20T12:46:41-04:00",
                "isLockedPro": false,
                "commentCount": 218,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: The Anti-Valeant",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23762",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "163989",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3582506-gilead-sciences-anti-valeant"
            }
        },
        {
            "id": "3585106",
            "type": "article",
            "attributes": {
                "publishOn": "2015-10-20T09:56:58-04:00",
                "isLockedPro": false,
                "commentCount": 97,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Is Large Cap Biotech One Of The Few Market Sectors With An Attractive Valuation?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "164042",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/3585106-is-large-cap-biotech-one-of-market-sectors-attractive-valuation"
            }
        },
        {
            "id": "3582376",
            "type": "article",
            "attributes": {
                "publishOn": "2015-10-19T11:53:08-04:00",
                "isLockedPro": false,
                "commentCount": 30,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: What Will It Take For Fair Valuation?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "65263",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "163986",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3582376-gilead-what-will-take-for-fair-valuation"
            }
        },
        {
            "id": "3581796",
            "type": "article",
            "attributes": {
                "publishOn": "2015-10-19T09:09:25-04:00",
                "isLockedPro": false,
                "commentCount": 55,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Time To Buy Gilead Sciences",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25562",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "163971",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3581796-time-to-buy-gilead-sciences"
            }
        },
        {
            "id": "3581626",
            "type": "article",
            "attributes": {
                "publishOn": "2015-10-19T08:11:02-04:00",
                "isLockedPro": false,
                "commentCount": 18,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Premarket Biotech Digest: Gilead's Upcoming Earnings, Setback For AstraZeneca, Zafgen Tumbles 50%",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "53222",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/3581626-premarket-biotech-digest-gileads-upcoming-earnings-setback-for-astrazeneca-zafgen-tumbles-50"
            }
        },
        {
            "id": "3581406",
            "type": "article",
            "attributes": {
                "publishOn": "2015-10-19T07:31:26-04:00",
                "isLockedPro": false,
                "commentCount": 27,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Biotech Is Coming Back, Buy Gilead",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "81356",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "163963",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3581406-biotech-is-coming-back-buy-gilead"
            }
        },
        {
            "id": "3571686",
            "type": "article",
            "attributes": {
                "publishOn": "2015-10-15T11:53:21-04:00",
                "isLockedPro": false,
                "commentCount": 58,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Buy Gilead: Hep-C Market Is At Least $500 Billion Over The Next 10 Years",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "82056",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "163741",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3571686-buy-gilead-hep-c-market-is-least-500-billion-over-next-10-years"
            }
        },
        {
            "id": "3574346",
            "type": "article",
            "attributes": {
                "publishOn": "2015-10-15T09:57:58-04:00",
                "isLockedPro": false,
                "commentCount": 47,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Great Prospects For Gilead Sciences",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22755",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "163805",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3574346-great-prospects-for-gilead-sciences"
            }
        },
        {
            "id": "3574086",
            "type": "article",
            "attributes": {
                "publishOn": "2015-10-15T08:42:54-04:00",
                "isLockedPro": false,
                "commentCount": 53,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "What Gilead's Buybacks Mean For Investors",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68315",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3574086-what-gileads-buybacks-mean-for-investors"
            }
        },
        {
            "id": "3565686",
            "type": "article",
            "attributes": {
                "publishOn": "2015-10-12T09:51:19-04:00",
                "isLockedPro": false,
                "commentCount": 26,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Premarket Biotech Digest: Understanding Multiple Sclerosis, Gilead's Hep C Sales, AstraZeneca Halts Trial",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "53222",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3565686-premarket-biotech-digest-understanding-multiple-sclerosis-gileads-hep-c-sales-astrazeneca"
            }
        },
        {
            "id": "3559056",
            "type": "article",
            "attributes": {
                "publishOn": "2015-10-08T07:34:21-04:00",
                "isLockedPro": false,
                "commentCount": 83,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead's Next Logical Acquisition, Part 1: NASH And Galmed",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "53222",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "163440",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3559056-gileads-next-logical-acquisition-part-1-nash-and-galmed"
            }
        },
        {
            "id": "3550596",
            "type": "article",
            "attributes": {
                "publishOn": "2015-10-05T08:05:12-04:00",
                "isLockedPro": false,
                "commentCount": 30,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Premarket Biotech Digest: Junk Bonds, Gilead Hep C Sales, Keytruda Approval",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "53222",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/3550596-premarket-biotech-digest-junk-bonds-gilead-hep-c-sales-keytruda-approval"
            }
        },
        {
            "id": "3545696",
            "type": "article",
            "attributes": {
                "publishOn": "2015-10-02T12:38:25-04:00",
                "isLockedPro": false,
                "commentCount": 155,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Will Rebound In The Fourth Quarter",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23762",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "163135",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3545696-gilead-will-rebound-in-fourth-quarter"
            }
        }
    ]
}